Tarsus Acquires Alkeus for $450M Upfront, Adding Phase 3 Stargardt Disease Drug

Tarsus Pharmaceuticals (TARS) announced August 6 that it will acquire privately held Alkeus Pharmaceuticals in a deal worth up to $800 million: $450 million upfront ($270 million in cash and $180 million in Tarsus stock) plus up to $350 million tied to regulatory and commercial milestones. The acquisition centers on gildeuretinol (ALK-001), a once-daily oral therapy for Stargardt disease, the most common inherited retinal disorder. It affects an estimated 30,000 to 50,000 Americans and has no FDA-approved treatment.

Gildeuretinol targets the underlying biology of Stargardt disease by reducing the formation of toxic vitamin A dimers that accumulate in the retina and drive progressive vision loss. By slowing this damage, the drug aims to preserve functional vision over years. This is a different approach from the anti-VEGF injections that dominate the wet AMD market: Stargardt is a genetic disease, not a vascular leak, so the biology calls for an oral small molecule rather than an ocular injection.

The drug is currently in the Phase 3 NORTHSTAR study, though data is not expected until 2029, making this a long-duration pipeline bet. Stargardt enrollment is slow because the ABCA4 mutation that causes the disease is rare even within a small patient population, and the primary endpoint (rate of retinal lesion growth over a two-year measurement window) demands patience. No competitor has an approved drug for Stargardt, so the first-to-market advantage is large if Tarsus can deliver.

Tarsus, valued at roughly $2.7 billion with shares at $65.33, is building a multi-franchise eye care company. Its commercial business rests on XDEMVY (lotilaner) for Demodex blepharitis, a condition caused by eyelid mites that affects roughly 25 million Americans. The Alkeus deal follows the iRenix acquisition that brought IRX-101, a retinal asset for geographic atrophy and diabetic macular edema. Gildeuretinol adds a third pillar: inherited retinal disease, a category where no oral disease-modifying therapy exists.

The $450 million upfront is a meaningful commitment for a company Tarsus’ size. Investors are buying a pipeline asset that will not produce data for three years and revenue for longer. The PDUFA date guide provides context on how FDA review timelines work, though gildeuretinol’s review is years from becoming relevant.

What to watch next: the Phase 3 NORTHSTAR enrollment update at Tarsus’ next quarterly call. Faster-than-expected enrollment could pull the 2029 data timeline forward; slower enrollment pushes it further out. That update, not the deal close, is the next value-moving event.